at the population level in patients with HFrEF eligible for SGLT2 inhibitor treatment, lead to an estimated relative risk reduction in all-cause mortality of 73%. 15 Authors of the guideline call ...

The new approach is designed to create a connection between the left and right atrial chambers of the heart in a single ...

Alleviant Medical announced that it received FDA investigational device exemption and breakthrough device designation for its ...

BiovitalsHF uses software algorithms and wearable sensors to help direct drug treatment for HFrEF, encourage patients ... It has been designed to follow guideline-directed medical therapy ...